EGFR and non-small cell lung carcinoma: These studies also confirmed the important role of miRNAs in osimertinib resistance; therefore, targeting them may improve and restore the sensitivity of NSCLC patients with inherent and acquired resistance to third-generation EGFR-TKIs.